RxDoctor Payments Data

Matthew Taylor, MD

Clinical Cardiac Electrophysiology · Idaho Falls, IDNPI 1033123658

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (52.4%), travel and lodging and education — rather than concentrated in one kind of arrangement. Medtronic accounts for 63.3% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2020 at $2,659 and has fallen 64.9% since, to $933 in 2025.

$8,597in general payments, 2019–2025

Across 145 payments — averaging $59.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$5K
  • Biosense Webster, Inc.$2K
  • Boston Scientific$992
  • Johnson & Johnson$337
  • Abbott$183
  • Novartis$22
  • plus $74 from 4 others
$11,155in research payments, 2019–2025

Across 2 payments — averaging $5577.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$11K
  • Abbott$250

What the payments were for

  • Travel & lodging$4,07347%
  • Food & beverage$4,50552%
  • Education$190%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few clinical cardiac electrophysiology providers in Idahoto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$79,221
Medicare patients
115
Services billed
278

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban12$16,386
Metoprolol Succinate32$285

Paid to pharmacies, not to this prescriber.

Other clinical cardiac electrophysiology in Idaho Falls

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →